에타너셉트 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "에타너셉트" in Korean language version.

refsWebsite

Global rank Korean rank

9nih.gov

4^th place

8doi.org

2^nd place

3^rd place

7fda.gov

447^th place

433^rd place

6web.archive.org

1^st place

5archive.org

6^th place

18^th place

3medicines.org.uk

3,823^rd place

2,321^st place

3europa.eu

68^th place

145^th place

2canada.ca

1,712^th place

1,155^th place

2funnelback.com

low place

2semanticscholar.org

11^th place

310^th place

1hpfb-dgpsa.ca

low place

1tga.gov.au

3,984^th place

1,245^th place

1drugs.com

399^th place

141^st place

1hres.ca

low place

1dukemednews.org

low place

1handle.net

102^nd place

307^th place

1cnn.com

28^th place

89^th place

archive.org (Global: 6^th place; Korean: 18^th place)

Peppel K, Crawford D, Beutler B (December 1991). “A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity”. 《The Journal of Experimental Medicine》 174 (6): 1483–1489. doi:10.1084/jem.174.6.1483. PMC 2119031. PMID 1660525.
Peppel K, Poltorak A, Melhado I, Jirik F, Beutler B (November 1993). “Expression of a TNF inhibitor in transgenic mice”. 《Journal of Immunology》 151 (10): 5699–5703. doi:10.4049/jimmunol.151.10.5699. PMID 7693816. S2CID 10859938.
Braun J, McHugh N, Singh A, Wajdula JS, Sato R (June 2007). “Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly”. 《Rheumatology》 46 (6): 999–1004. doi:10.1093/rheumatology/kem069. PMID 17389658.
Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O'Brien C 외 (August 2007). “Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection”. 《Journal of Immunology》 179 (3): 1872–1883. doi:10.4049/jimmunol.179.3.1872. PMID 17641054.
Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C 외 (September 2005). “Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer”. 《Journal of Clinical Oncology》 23 (25): 5950–5959. doi:10.1200/JCO.2005.04.127. PMID 16135466.

canada.ca (Global: 1,712^th place; Korean: 1,155^th place)

“Health Canada New Drug Authorizations: 2016 Highlights”. 《Health Canada》. 2017년 3월 14일. 2024년 4월 7일에 확인함.
“Arthritis”. 《Health Canada》. 2018년 5월 8일. 2024년 4월 13일에 확인함.

cnn.com (Global: 28^th place; Korean: 89^th place)

money.cnn.com

“Wyeth and Amgen heighten warning of life-threatening infections on skin drug Enbrel”. 2008년 5월 5일에 원본 문서에서 보존된 문서. 2008년 5월 2일에 확인함.

doi.org (Global: 2^nd place; Korean: 3^rd place)

dx.doi.org

Feldmann M, Maini RN (October 2003). “Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases”. 《Nature Medicine》 9 (10): 1245–1250. doi:10.1038/nm939. PMID 14520364. S2CID 52860838.
Peppel K, Crawford D, Beutler B (December 1991). “A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity”. 《The Journal of Experimental Medicine》 174 (6): 1483–1489. doi:10.1084/jem.174.6.1483. PMC 2119031. PMID 1660525.
Peppel K, Poltorak A, Melhado I, Jirik F, Beutler B (November 1993). “Expression of a TNF inhibitor in transgenic mice”. 《Journal of Immunology》 151 (10): 5699–5703. doi:10.4049/jimmunol.151.10.5699. PMID 7693816. S2CID 10859938.
Braun J, McHugh N, Singh A, Wajdula JS, Sato R (June 2007). “Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly”. 《Rheumatology》 46 (6): 999–1004. doi:10.1093/rheumatology/kem069. PMID 17389658.
Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E 외 (April 2015). “TNF-alpha inhibitors for ankylosing spondylitis”. 《The Cochrane Database of Systematic Reviews》 4 (4): CD005468. doi:10.1002/14651858.CD005468.pub2. PMID 25887212.
Kim PJ, Lansang RP, Vender R (July 2023). “A Systematic Review and Meta-Analysis of Injection Site Reactions in Randomized-Controlled Trials of Biologic Injections”. 《Journal of Cutaneous Medicine and Surgery》 27 (4): 358–367. doi:10.1177/12034754231188444. PMC 10486173 |pmc= 값 확인 필요 (도움말). PMID 37533141.
Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O'Brien C 외 (August 2007). “Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection”. 《Journal of Immunology》 179 (3): 1872–1883. doi:10.4049/jimmunol.179.3.1872. PMID 17641054.
Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C 외 (September 2005). “Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer”. 《Journal of Clinical Oncology》 23 (25): 5950–5959. doi:10.1200/JCO.2005.04.127. PMID 16135466.

drugs.com (Global: 399^th place; Korean: 141^st place)

“Etanercept Use During Pregnancy”. 《Drugs.com》. 2020년 1월 24일. 2020년 8월 13일에 확인함.

dukemednews.org (Global: low place; Korean: low place)

“Arthritis Drug Effective for Depression in Psoriasis Sufferers”. 2007년 10월 20일에 원본 문서에서 보존된 문서. 2008년 1월 10일에 확인함.

europa.eu (Global: 68^th place; Korean: 145^th place)

ema.europa.eu

“Nepexto EPAR”. 《European Medicines Agency》. 2020년 3월 24일. 2023년 3월 4일에 확인함.
“Enbrel EPAR”. 《European Medicines Agency (EMA)》. 2018년 9월 17일. 2020년 4월 2일에 확인함. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

ec.europa.eu

“Nepexto Product information”. 《Union Register of medicinal products》. 2023년 3월 3일에 확인함.

fda.gov (Global: 447^th place; Korean: 433^rd place)

accessdata.fda.gov

“Drugs@FDA: FDA-Approved Drugs”.
Weiss KD (2002년 1월 15일). “Approval of Etanercept for treatment of psoriatic arthritis”. Letter to Sally Gould. U.S. Food and Drug Administration (FDA). 2015년 4월 14일에 확인함.
Keegan P (2003년 7월 24일). “Approval of Etanercept for treatment of ankylosing spondylitis” (PDF). Letter to Douglas Hunt. U.S. Food and Drug Administration (FDA). 2015년 4월 14일에 확인함.
Walton M (2004년 4월 30일). “Approval of Etanercept for treatment of moderate to severe plaque psoriasis” (PDF). Letter to Douglas Hunt. U.S. Food and Drug Administration (FDA). 2015년 4월 14일에 확인함.

fda.gov

Siegel YP (1998년 11월 2일). “Approval of Etanercept for treatment of rheumatoid arthritis” (PDF). Letter to Sally Gould. U.S. Food and Drug Administration (FDA). 2015년 4월 14일에 확인함.
Weiss KD (1999년 5월 27일). “Approval of Etanercept for treatment of polyarticular course juvenile rheumatoid arthritis (JRA)” (PDF). Letter to Sally Gould. U.S. Food and Drug Administration (FDA). 2015년 4월 14일에 확인함.
《Safety Update on TNF- α Antagonists: Infliximab and Etanercept》 (PDF). U.S. Food and Drug Administration (FDA). 13–14쪽. 2015년 9월 24일에 원본 문서 (PDF)에서 보존된 문서. 2013년 12월 20일에 확인함.

funnelback.com (Global: low place; Korean: low place)

tga-search.clients.funnelback.com

“Etera ARTG”. 《Therapeutic Goods Administration (TGA)》. 2021년 6월 13일에 원본 문서에서 보존된 문서. 2021년 6월 12일에 확인함.
“Rymti ARTG”. 《Therapeutic Goods Administration (TGA)》. 2021년 6월 13일에 원본 문서에서 보존된 문서. 2021년 6월 12일에 확인함.

handle.net (Global: 102^nd place; Korean: 307^th place)

hdl.handle.net

World Health Organization (2019). 《World Health Organization model list of essential medicines: 21st list 2019》. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

hpfb-dgpsa.ca (Global: low place; Korean: low place)

dhpp.hpfb-dgpsa.ca

“Regulatory Decision Summary for Erelzi”. 《Drug and Health Products Portal》. 2017년 4월 6일. 2024년 4월 13일에 확인함.

hres.ca (Global: low place; Korean: low place)

hpr-rps.hres.ca

“Rymti Summary Basis of Decision”. 《Health Canada》. 2014년 10월 23일. 2023년 5월 27일에 원본 문서에서 보존된 문서. 2023년 3월 10일에 확인함.

medicines.org.uk (Global: 3,823^rd place; Korean: 2,321^st place)

“Benepali 25 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)”. 《(emc)》. 2021년 1월 25일. 2021년 6월 12일에 확인함.
“Enbrel 25mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC)”. 《(emc)》. 2021년 6월 8일. 2021년 6월 12일에 확인함.
“Erelzi 50 mg solution for injection in pre filled pen - Summary of Product Characteristics (SmPC)”. 《(emc)》. 2021년 5월 25일. 2021년 6월 12일에 확인함.

nih.gov (Global: 4^th place; Korean: 4^th place)

ncbi.nlm.nih.gov

Feldmann M, Maini RN (October 2003). “Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases”. 《Nature Medicine》 9 (10): 1245–1250. doi:10.1038/nm939. PMID 14520364. S2CID 52860838.
Peppel K, Crawford D, Beutler B (December 1991). “A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity”. 《The Journal of Experimental Medicine》 174 (6): 1483–1489. doi:10.1084/jem.174.6.1483. PMC 2119031. PMID 1660525.
Peppel K, Poltorak A, Melhado I, Jirik F, Beutler B (November 1993). “Expression of a TNF inhibitor in transgenic mice”. 《Journal of Immunology》 151 (10): 5699–5703. doi:10.4049/jimmunol.151.10.5699. PMID 7693816. S2CID 10859938.
Braun J, McHugh N, Singh A, Wajdula JS, Sato R (June 2007). “Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly”. 《Rheumatology》 46 (6): 999–1004. doi:10.1093/rheumatology/kem069. PMID 17389658.
Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E 외 (April 2015). “TNF-alpha inhibitors for ankylosing spondylitis”. 《The Cochrane Database of Systematic Reviews》 4 (4): CD005468. doi:10.1002/14651858.CD005468.pub2. PMID 25887212.
Kim PJ, Lansang RP, Vender R (July 2023). “A Systematic Review and Meta-Analysis of Injection Site Reactions in Randomized-Controlled Trials of Biologic Injections”. 《Journal of Cutaneous Medicine and Surgery》 27 (4): 358–367. doi:10.1177/12034754231188444. PMC 10486173 |pmc= 값 확인 필요 (도움말). PMID 37533141.
Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O'Brien C 외 (August 2007). “Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection”. 《Journal of Immunology》 179 (3): 1872–1883. doi:10.4049/jimmunol.179.3.1872. PMID 17641054.
Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C 외 (September 2005). “Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer”. 《Journal of Clinical Oncology》 23 (25): 5950–5959. doi:10.1200/JCO.2005.04.127. PMID 16135466.

dailymed.nlm.nih.gov

“Enbrel- etanercept solution Enbrel- etanercept kit”. 《DailyMed》. 2021년 4월 17일에 확인함.

semanticscholar.org (Global: 11^th place; Korean: 310^th place)

api.semanticscholar.org

Feldmann M, Maini RN (October 2003). “Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases”. 《Nature Medicine》 9 (10): 1245–1250. doi:10.1038/nm939. PMID 14520364. S2CID 52860838.
Peppel K, Poltorak A, Melhado I, Jirik F, Beutler B (November 1993). “Expression of a TNF inhibitor in transgenic mice”. 《Journal of Immunology》 151 (10): 5699–5703. doi:10.4049/jimmunol.151.10.5699. PMID 7693816. S2CID 10859938.

tga.gov.au (Global: 3,984^th place; Korean: 1,245^th place)

“Australian Public Assessment Report for Etanercept” (PDF). Feb 2021.

web.archive.org (Global: 1^st place; Korean: 1^st place)

“Etera ARTG”. 《Therapeutic Goods Administration (TGA)》. 2021년 6월 13일에 원본 문서에서 보존된 문서. 2021년 6월 12일에 확인함.
“Rymti ARTG”. 《Therapeutic Goods Administration (TGA)》. 2021년 6월 13일에 원본 문서에서 보존된 문서. 2021년 6월 12일에 확인함.
“Rymti Summary Basis of Decision”. 《Health Canada》. 2014년 10월 23일. 2023년 5월 27일에 원본 문서에서 보존된 문서. 2023년 3월 10일에 확인함.
“Arthritis Drug Effective for Depression in Psoriasis Sufferers”. 2007년 10월 20일에 원본 문서에서 보존된 문서. 2008년 1월 10일에 확인함.
“Wyeth and Amgen heighten warning of life-threatening infections on skin drug Enbrel”. 2008년 5월 5일에 원본 문서에서 보존된 문서. 2008년 5월 2일에 확인함.
《Safety Update on TNF- α Antagonists: Infliximab and Etanercept》 (PDF). U.S. Food and Drug Administration (FDA). 13–14쪽. 2015년 9월 24일에 원본 문서 (PDF)에서 보존된 문서. 2013년 12월 20일에 확인함.

에타너셉트 (Korean Wikipedia)

archive.org (Global: 6th place; Korean: 18th place)

canada.ca (Global: 1,712th place; Korean: 1,155th place)

cnn.com (Global: 28th place; Korean: 89th place)

money.cnn.com

doi.org (Global: 2nd place; Korean: 3rd place)

dx.doi.org

drugs.com (Global: 399th place; Korean: 141st place)

dukemednews.org (Global: low place; Korean: low place)

europa.eu (Global: 68th place; Korean: 145th place)

ema.europa.eu

ec.europa.eu

fda.gov (Global: 447th place; Korean: 433rd place)

accessdata.fda.gov

fda.gov

funnelback.com (Global: low place; Korean: low place)

tga-search.clients.funnelback.com

handle.net (Global: 102nd place; Korean: 307th place)

hdl.handle.net

hpfb-dgpsa.ca (Global: low place; Korean: low place)

dhpp.hpfb-dgpsa.ca

hres.ca (Global: low place; Korean: low place)

hpr-rps.hres.ca

medicines.org.uk (Global: 3,823rd place; Korean: 2,321st place)

nih.gov (Global: 4th place; Korean: 4th place)

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

semanticscholar.org (Global: 11th place; Korean: 310th place)

api.semanticscholar.org

tga.gov.au (Global: 3,984th place; Korean: 1,245th place)

web.archive.org (Global: 1st place; Korean: 1st place)

archive.org (Global: 6^th place; Korean: 18^th place)

canada.ca (Global: 1,712^th place; Korean: 1,155^th place)

cnn.com (Global: 28^th place; Korean: 89^th place)

doi.org (Global: 2^nd place; Korean: 3^rd place)

drugs.com (Global: 399^th place; Korean: 141^st place)

europa.eu (Global: 68^th place; Korean: 145^th place)

fda.gov (Global: 447^th place; Korean: 433^rd place)

handle.net (Global: 102^nd place; Korean: 307^th place)

medicines.org.uk (Global: 3,823^rd place; Korean: 2,321^st place)

nih.gov (Global: 4^th place; Korean: 4^th place)

semanticscholar.org (Global: 11^th place; Korean: 310^th place)

tga.gov.au (Global: 3,984^th place; Korean: 1,245^th place)

web.archive.org (Global: 1^st place; Korean: 1^st place)